title: Neuroimaging as endpoints in clinical trials: are we there yet? Perspective from the first Provence workshop.
authors.affiliation: Regenerative Neuroscience Group, Neuropsychiatric Institute, Prince of Wales Hospital, Randwick, Sydney, NSW 2031, Australia. michaelv@unsw.edu.au
authors.forename: M
authors.initials: M
authors.lastname: Valenzuela
authors.forename: D
authors.initials: D
authors.lastname: Bartrés-Faz
authors.forename: F
authors.initials: F
authors.lastname: Beg
authors.forename: A
authors.initials: A
authors.lastname: Fornito
authors.forename: E
authors.initials: E
authors.lastname: Merlo-Pich
authors.forename: U
authors.initials: U
authors.lastname: Müller
authors.forename: D
authors.initials: D
authors.lastname: Öngür
authors.forename: A W
authors.initials: AW
authors.lastname: Toga
authors.forename: M
authors.initials: M
authors.lastname: Yücel
mesh_terms: D001921:Brain / Q000187:drug effects / Q000473:pathology; D002491:Central Nervous System Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods*; D055808:Drug Discovery; D023381:Endpoint Determination; D006801:Humans; D059906:Neuroimaging; D009929:Organ Size; D057285:Precision Medicine; D016896:Treatment Outcome
chemical_list: D002491:Central Nervous System Agents